High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma

Journal of B.U.ON.

Volumn 20, Issue 5, 2015, Pages 1267-1275

  Wang, Jun ^a   Wen, Jianbo ^a   Yi, Rui ^a   Liu, Fang ^a   Zhou, Jinbo ^a   Liu, Geliang ^a   Li, Qin ^a   Yang, Zhou ^a   Su, Xiaoqing ^a  

^a JiangXi PingXiang Peoples Hospital   (China)

Author keywords

Clear cell renal cell carcinoma; PMS2; SETD2

Indexed keywords

AZD 6482; PHOSPHATIDYLINOSITOL 3 KINASE BETA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TGX 221; UNCLASSIFIED DRUG; 2-(1-(7-METHYL-2-MORPHOLIN-4-YL-4-OXO-4H-PYRIDO(1,2-A)PYRIMIDIN-9-YL)ETHYLAMINO)BENZOIC ACID; ANTHRANILIC ACID DERIVATIVE; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 6; HISTONE LYSINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CB PROTEIN, HUMAN; PYRIMIDINONE DERIVATIVE; SET2 PROTEIN, HUMAN;

APC GENE; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CDK6 GENE; CELL MIGRATION; CLEAR CELL CARCINOMA; COLONY FORMATION; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; GENE INTERACTION; GENE MUTATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; PIK3CA GENE; RB1 GENE; SETD2 GENE; TUMOR INVASION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; GENE REGULATORY NETWORK; GENETICS; KIDNEY NEOPLASMS; MUTATION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 6; GENE REGULATORY NETWORKS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; KIDNEY NEOPLASMS; MUTATION; ORTHO-AMINOBENZOATES; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINONES;

EID: 84953856110     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 2012;22:2089-2100.
2. Guo G, Gui Y, Gao S et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genetics 2012;44:17-19.
3. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463:360-363.
4. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469:539-542.
5. Carvalho S, Vitor AC, Sridhara SC et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. eLife. 2014;3:e02482.
6. Li F, Mao G, Tong D et al. The histone mark H 3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 2013;153:590-600.
7. Schmidt CK, Jackson SP. On your mark, get SET (D2), go! H3K36me3 primes DNA mismatch repair. Cell 2013;153:513-515.
8. Pfister SX, Ahrabi S, Zalmas LP et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep 2014;7:2006-2018.
9. Hwang C, Heath EI. The Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma. J Clin Oncol 2014;32:729-734.
10. Stein A, Bellmunt J, Escudier B et al. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol 23;64:994-1002.
11. Feng C, Ding G, Jiang H, Ding Q, Wen H. Loss of MLH1 confers resistance to PI3KP inhibitors in renal clear cell carcinoma with SETD2 mutation. Tumor Biol 2015;36:3457-3464.
12. Feng C, Sun Y, Ding G et al. PI3Kbeta inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways. Sci Rep 2015;5:9465.
13. Cancer Genome Atlas Research. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-49.
14. http://cancergenome.nih.gov/publications/publicationguidelines
15. Garnett MJ, Edelman EJ, Heidorn SJ et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-575.
16. Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Sign 2013:6:11.
17. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-404.
18. Yang W, Soares J, Greninger P et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013;41(Database issue):D955-61.
19. Ding G, Feng C, Jiang H et al. Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition. PloS One 2013;8(10):e77400.
20. Feng C, Wu Z, Guo T et al. BLCA-4 expression is related to MMP-9, VEGF, IL-1α and IL-8 in bladder cancer but not to PEDF, TNF - A or angiogenesis. Pathologie Biologie 2012;60:e36-e40.
21. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;37:1769-1770.
22. Choi YJ, Oh HR, Choi MR et al. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. Hum Pathol 2014;45:1674-1681.
23. Hakimi AA, Ostrovnaya I, Reva B et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013;19:3259-3267.
24. Manceau G, Marisa L, Boige V et al. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. Cancer Med 2015;4:371-382.
25. Paternot S, Colleoni B, Bisteau X, Roger PP. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes. Cell Cycle (Georgetown, Tex) 2014;13:2879-2888.
26. Shepherd PR, Denny WA. Beta-testing of PI3-kinase inhibitors: is beta better? Cancer Discov 2012;2:393-394.
27. Ni J, Liu Q, Xie S et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. Cancer Discov 2012;2:425-433